The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD 1) and a selective inhibitor of indoleamine 2 3 dioxygenase 1 (IDO1) and the use of the combination therapies for the treatment of cancer and in particular for treating cancers that express PD L1.